Treatment of adult acute leukemia

Current Opinion in Oncology

Volumn 9, Issue 1, 1997, Pages 18-25

  Büchner, Thomas ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE;

ACUTE LEUKEMIA; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CHROMOSOME DELETION; GENE EXPRESSION REGULATION; HIGH RISK POPULATION; HUMAN; MALIGNANT TRANSFORMATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REMISSION; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0030948545     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199701000-00004     Document Type: Review

References (61)

1. Pedersen-Bjergaard J, Rowley JD: The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994, 83:2780-2786.
2. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P: Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia [abstract]. Blood 1995, 86(suppl 1):435.
3. Hoffmann L, Möller P, Pedersen Bjergaard J, Waage A, Pedersen M, Hirsch FR: Therapy-related acute promyelocytic leukemia t(15;17) (q22;q12) following chemotherapy with drugs targeting DNA topoisomerase: II. A report of two cases and a review of the literature. Ann Oncol 1995, 6:781-788.
4. Gillis S, Sofer O, Zelig O, Dann EJ, Lotan H, Ben Yehuda D, Isacson R, Rachmilewitz EA, Ben-Bassat I, Polliack A: Acute promyelocytic leukemia with t(15;17) following treatment of Hodgkin's disease: a report of 4 cases. Ann Oncol 1995, 6:777-779.
5. Douer D, Preston-Martin S, Chang E, Nichols PW, Watkins KJ, Levine AM: High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood 1996, 87:308-313. Important contribution to epidemiology of APL and its high frequency in Latinos.
6. Sutherland HJ, Blair A, Zapf RW: Characterization of a hierarchy in human acute myeloid leukemia progenitor cells. Blood 1996, 87:4754-4761. Important characterization of the nature of leukemic progenitors using long-term culturing methods.
7. - subpopulation of acute myeloid leukemia. Blood 1996, 87:2187-2194. Systematic work to characterize AML progenitor cells by long-term culturing and transfer into severe combined immunodeficient mice.
8. Bonnet D, Dick JE: Purification and characterization of a cell initiating human acute leukemia after transplantation into NOD-SCID mice [abstract]. Blood 1995, 86(suppl 1):435.
9. Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T, Takenaka K, Mizuno S, Gondo H, Okamura T, et al.: Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996, 87:4789-4796. Detection of AML1/ETO transcripts in various clonogeneic progenitors from bone marrow of patients with t(8;21) in long-term remission. Very important evidence that the leukemic stem cell is a multipotent progenitor.
10. Haferlach T, Winkemann M, Löffler H, Schoch R, Gassmann W, Fonatsch C, Schoch C, Poetsch M, Weber-Matthiesen K, Schlegelberger B: The abnormal eosinophils are part of the leukemic cell population in acute myelomonocytic leukemia with abnormal eosinophils (AML M4Eo) and carry the pericentric inversion 16: a combination of May-Grünwald-Giemsa staining and fluorescence in situ hydridization. Blood 1996, 87:2459-2463. This important finding demonstrates that the cell producing AML M4EO is a progenitor of at least the neutrophil, monocyte, and eosinophil lineages.
11. - cells from patients with AML of various subtypes do show AML typical clonal chromosome abnormalities. Substantial evidence that malignant transformation occurs in multipotent stem cells.
12. Mane JP, Zittoun R, Sikic BI: Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlation with treatment outcome and in vitro drug sensitivity. Blood 1991, 78:586-592.
13. Campos L, Guyotat D, Archimbaud E, Calmard Oriol P, Tsuruo T, Troncy J, Trielle D, Fiere D: Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992, 79:473-476.
14. Guerci A, Merlin JL, Missoum N, Feldmann L, Marchai S, Witz F, Rose C, Guerci O: Predictive value of treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 1995, 85:2147-2153.
15. Hunault M, Zhou D, Ramon S, Delmer A, Cadiou M, Perrot JY, Marie JP, Zittoun R: MDR Expression in acute myeloid leukemia (AML): major prognosis significance in multivariate analysis [abstract]. Blood 1995, 86(suppl 1):269.
16. Leith CP, Kopecky KJ, Chen IM, Godwin JE, Appelbaum FR, Head DR, Willmann CL: MDR1 expression is highly predictive for achievement of complete remission (CR) in acute myeloid leukemia (AML) in the elderly: a Southwest Oncology Group Study [abstract]. Blood 1995, 86(suppl 1):269.
17. Broxtermann HJ, Sonneveld P, Feller N, Ossenkoppele GJ, Währer DCR, Eekman CA, Schoester M, Lankelma J, Pinedo HM, Löwenberg B, Schuurhuis GJ: Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays of P-glycoprotein expression and activity. Blood 1996, 87:4809-4816. Methodologic standardization of quantitative monitoring P-glycoprotein and MDR1 in leukemias.
18. Sperling C, Büchner T, Creutzig U, Ritter J, Harbott J, Fonatsch C, Sauerland C, Mielcarek M, Maschmeyer G, Löffler H, Ludwig WD: Clinical, morphologic, cytogenetic and prognostic implications of CD34 expression in childhood and adult de novo AML. Leuk Lymphoma 1995, 17:417-426.
19. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, et al.: A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996, 87:1710-1717. This excellent randomized trial demonstrates the long-term effect of intensified induction treatment by high-dose cytarabine. Remarkable cure rates were demonstrated on an intent-to-treat basis.
20. Büchner T, Hiddemann W, Löffler H, Gassmann W, Maschmeyer G, Ludwig WD, Aul C, Lengfelder E, Boeckmann A, Sauerland MC, Heinecke A: Double induction in AML comparing high with Standard dose Ara-C: hematotoxicity and antileukemic efficacy [abstract]. Blood 1994, 84(suppl 1):232.
21. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulmann P, Omura GA, Moore JO, McIntyre OR, Frei E: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994, 331:896-942.
22. Büchner T, Urbanitz D, Hiddemann W, Rühl H, Ludwig WD, Fischer J, Aul HC, Vaupel HA, Kuse R, Zeile G, et al.: Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985, 3:1583-1589.
23. Büchner T, Hiddemann W, Löffler H, Fonatsch C, Gassmann W, Maschmeyer G, Ludwig WD, Heyll A, Hossfeld D, Sauerland C, Heinecke A: Treatment of AML in the elderly: full-dose versus reduced dose induction treatment [abstract]. Blood 1995, 86(suppl 1):434.
24. Rees JKH, Gray RG, Swirsky D, Hayhoe FGJ: Principal results of the Medical Research Council's 8th acute myeloid leukemia trial. Lancet 1986, 11:1236-1241.
25. Preisler H, Davis RB, Kirshner J, Dupre E, Richards III F, Hoagland C, Kopel S, Levy RN, Carey R, Schulmann P, Gottlieb AJ, McIntyre OR: Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study. Blood 1987, 69:1441-1449.
26. Löwenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, Cauchie C, Peetermans M, Solbu G, Suciu S, Stryckmans P: On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989, 7:1268-1274.
27. Dillmann RO, Davis RB, Green MR, Weiss RB, Gottlieb AJ, Caplan S, Kopel S, Preisler H, McIntyre OR, Schiffer C: A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood 1991, 78:2520-2526.
28. Stone RM, Berg DT, George SL, Dodge RK, Pagucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995, 332:1671-1677. Large controlled trial on GM-CSF after chemotherapy in older adults showing no therapeutic benefit. The product (E. coli-derived GM-CSF) and discontinuation of both GM-CSF and placebo in one third of patients may have contributed to the negative results.
29. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiernik PH: A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995, 86:457-462. Demonstration of clear hematologic and therapeutic effects of GM-CSF (yeast) after chemotherapy in older adults.
30. Zittoun R, Suciu S, Mandelli F, de Witte T, Thaler J, Stryckmans P, Hayat M, Peetermans M, Cadiou M, Solbu G, et al.: Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1996, 14:2150-2159.
31. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzenneau G, Tilly H, Yver A, Degos L: A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995, 332:1678-1683. In this important study on G-CSF after chemotherapy in older adults, remarkable effects on neutrophil recovery and complete remission rate were achieved. Overall survival was not improved, but treatment of failures is not defined.
32. Heil G, Hoelzer D, Sanz MA, Lechner K, Lin Yin, Pane G, Noens L, Ho J, O'Brien CO, Matcham J, Barge A: Results of a randomized double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de novo acute myeloid leukemia [abstract]. Blood 1995, 86(suppl 1):267.
33. Ohno R, Mivawaki S, Hatake K, Tomonaga M, Kobavashi T, Tanimoto M, Masaoka T, Miura Y, Takaku F, Ohashi Y, Motovoshi K: Macrophage-colony stimulating factor (M-CSF) reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia (AML): a double-blind controlled study [abstract]. Blood 1995, 86(suppl 1):266.
34. Büchner T, Hiddemannn W, Wörmann B, Zühlsdorf M, Rottmann R, Innig G, Maschmeier G, Ludwig WD, Sauerland MC, Heinecke A: Hematopoietic growth factors in acute myeloid leukemia: supportive and priming effects. Semin Oncol 1997, 24:1-9.
35. Löwenberg B, Suciu S, Zittoun R, Ossenkoppele G, Boogaerts MA, Wijermans P, Veilenga E, Berneman Z, Dekker AW, Sonneveld P, et al.: GM-CSF during as well as after induction chemotherapy (CT) in elderly patients with acute myeloid leukemia (AML): the EORTC-HOVON phase III trial (AML 11). Blood 1995, 86(suppl 1):433a.
36. Heil G, Chadid L, Hoelzer D, Seipelt G, Mitrou P, Huber C, Kolbe K, Mertelsmann R, Lindemann A, Frisch J, et al.: GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). Leukemia 1995, 9:3-9.
37. Büchner T, Hiddemann W, Wörmann B, Zühlsdorf M, Rottmannn R, Innig G, Maschmeier G, Ludwig WD, Sauerland MC, Heinecke A, for the AMLCG: Growth factors in AML: updates. Heamatology and Blood Transfusion 1997, 40:445-455.
38. Witz F, Harousseau JL, Sadoun A, Guyotat D, Berthou C, Cahn JY, Gardin C, Lioure B, Witz B, Desablens B, et al.: Granulocyte-macrophage colony-stimulating factor during and after remission induction treatment for elderly patients with acute myeloid leukemia. Haematol Blood Transfusion 1997, 40:852-856.
39. Frassoni F, Labopin M, Gluckman E, Prentice HG, Vernant JP, Zwaan F, Granena A, Gahrton G, de Witte T, Gratwohl A, et al.: Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time: a report of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (ABMT). Bone Marrow Transplant 1996, 17:13-18. Collected data from European BMT centers show a significant trend toward reduction in treatment-related mortality over the years, whereas relapse rates are constant.
40. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J, Storb R, Buckner CD: Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995, 85:1655-1658.
41. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Löffler H, Hunter A, Russel NH: Primary transplanation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995, 85:1666-1672.
42. + blood cells. Blood 1995, 86:2500-2508 First experiences with combined bone marrow and blood immunoselected allogeneic stem cell transplantation.
43. + blood cells. Blood 1996, 87:4903-4909. First demonstration of effective allogeneic transplantation of immunoselected blood stem cells. Relevant data about GVHD in this setting.
44. Kolb H-J, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, et al.: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86:2041-2050. As previously shown in patients with chronic myelocytic leukemia, durable remissions were also produced in some patients with AML by adoptive immunotherapy. One of the novel approaches to be addressed in future trials.
45. Gorin NC, Labopin M, Fouillard L, Gluckman E, Jacobsen N, Vernant JP, Boogaertz M, Witz E, Harousseau JL, Gratwohl A, Ringden O, on behalf of the acute leukemia working party of EBMT: Autologous (ABMT) versus unrelated (MUD) marrow transplantation for acute leukemia: a retrospective survey from the European Cooperative Group for Blood and Marrow Transplantation (EBMT)[abstract]. Blood 1995, 86(suppl 1):617.
46. Cahn JY, Labopin M, Mandelli F, Goldstone AH, Eberhardt K, Reiffers J, Ferrant A, Franklin I, Hervé P, Gratwohl A, Gorin NC: Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: a retrospective analysis of the European Bone Marrow Transplant Group. Blood 1995, 85:575-579.
47. Körbling M, Fliedner T M, Holle R, Magrin S, Baumann M, Holdermann E, Eberhardt K: Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (pABMT) in standard risk AML: influence of source and cell composition of the autograft on hemopoietic reconstitution and disease-free survival. Bone Marrow Transplant 1991, 7:343-349.
48. Demirer T, Bensinger WI, Rowley S, Appelbaum FR, Petersen FB, Chauncey T, Fefer A, Buckner CD: Comparison of granulocyte-colony stimulating factor (rhG-CSF) mobilized peripheral blood stem cells (PBSC) and bone marrow for autologous transplantation in patients with acute myelogenous leukemia (AML) [abstract]. Blood 1995, 86(suppl 1):99.
49. Reichle A, Bross K, Reng M, Hennemann B, Krause St, Gatsch L, Andreesen R: Sequential mobilization of CD34 positive cells during induction and consolidation treatment in acute myelogenous leukemia (AML). Onkologie Int J Canc Res Treatment 1995, 18:13.
50. Bloomfield CD, Lawrence D, Arthur DC, Berg DT, Schiffer CA, Mayer: Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic [abstract]. Blood 1994, 84(suppl 1):111.
51. Hiddemann W, Fonatsch C, Wörmann B, Heinecke A, Sauerland C, Scharnhorst S, Büchner TH, for the German AML Cooperative Group: Cytogenetic subgroups of AML and outcome from high dose versus conventional dose ARA-C as part of doupble induction therapy [abstract]. Blood 1995, 86(suppl 1):267.
52. Gale RP, Horowitz MM, Weiner RS, Ash RC, Atkinson K, Babu R, Dicke KA, Klein JP, Lowenberg B, Reiffers J, et al.: Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplantation 1995, 16:203-208. First publication on cytogenetic prognostic groups and their role in determining the outcome of allogeneic BMT.
53. Burnett AK, Goldstone AH, Stevens R, Hann I, Rees JK, Wheatley K, for the UK MRC Leukaemia Working Parties: Biological characteristics of disease determine the outcome of allogeneic or autologous BMT in AML CR1 [abstract]. Blood 1995, 86(suppl 1):616.
54. Gorin NC, Labopin M, Frassoni F, Prentice HG, Cahn JY, Reiffers J, Boogaerts M, Bandini G, Löwenberg B, Attal M, Ferrant A: Karyotype in acute myeloblastic leukemia (AML): prognostic significance in bone marrow transplantation in first remission (CR1). Exp Hematol 1996, 24:1124.
55. Groupe Francais de Cytogenetique Hematologique: Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. A collaborative study. Blood 1996, 87:3135-3142. Large analysis of well-studied cytogenetic abnormalities according to prognosis in adult ALL.
56. Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, Duggan D, Davey FR, Sobol RE, Frankel SR, et al.: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811. Blood 1995, 85:2025-2037.
57. Hoelzer D, Ludwig W-D, Thiel E, Gassmann W, Löffler H, Fonatsch C, Rieder H, Heil G, Heinze B, Arnold R, et al.: Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996, 87:495-508. Impressive demonstration of subtype-specific strategy shifting prognosis from poor to favorable.
58. Ottmann OG, Hoelzer D, Gracien E, Ganser A, Kelly K, Reutzel R, Lipp Th, Busch FW, Schwonzen M, Heil G, et al.: Concomitant granulocyte colony stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood 1995, 86:444-450. First report on long-term concommittant G-CSF and chemotherapy with benefits in keeping the time schedule.
59. Zhang M-J, Hoelzer D, Horowrtz MM, Gale RP, Messerer D, Klein JP, Löffler H, Sobocinski KA, Thiel E, Weisdorf DJ, for the Acute Lymphoblastic Leukemia Working Committee: Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. Ann Intern Med 1995, 123:428-431. Confirmation of a previous report showing equivalence in outcome for allogeneic transplantation and chemotherapy in adult ALL.
60. Sebban C, Lepage E, Vernant J-P, Gluckman E, Attal M, Reiffers J, Sutton L, Racadot E, Michailet M, Maraninchi D, Dreyfus F, Fiere D, for the French Group of Therapy of Adult Acute Lymphblastic Leukemia: Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. J Clin Oncol 1994, 12:2580-2587.
61. Attal M, Biaise D, Marit G, Payen C, Michallet M, Vernant J-P, Sauvage C, Troussard X, Nedellec G, Pico J, et al., for the BGMT Group: Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1995, 86:1619-1628. Useful data comparing aliogeneic with autologous BMT.